Literature DB >> 12874013

Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.

Hans J J van der Vliet1, Johan W Molling, Nobusuke Nishi, Allan J Masterson, Wendy Kölgen, Steven A Porcelli, Alfons J M van den Eertwegh, B Mary E von Blomberg, Herbert M Pinedo, Giuseppe Giaccone, Rik J Scheper.   

Abstract

CD1d-restricted natural killer T (NKT) cells play important regulatory roles in various immune responses. NKT cell-derived T helper (Th) 1 cytokines are important in the induction of antitumor immune responses in mice. Because the CD1d-restricted Valpha24(+) Vbeta11(+) NKT cell population in cancer patients is decreased both in size and in its capacity to secrete IFN-gamma, therapeutic strategies based on reconstitution of type 1 polarized Valpha24(+) Vbeta11(+) NKT cells merit additional investigation. Here, we report the simultaneous strong expansion and type 1 polarization of human invariant Valpha24(+) Vbeta11(+) NKT cells using alpha-galactosylceramide-loaded type 1 dendritic cells and interleukin 15. Type 1 polarized Valpha24(+) Vbeta11(+) NKT cells produced high levels of IFN-gamma, tumor necrosis factor alpha, and granulocyte macrophage colony-stimulating factor, and induced strong cytotoxicity in Jurkat cells in an alpha-galactosylceramide-dependent manner. Importantly, the cytokine profile of Valpha24(+) Vbeta11(+) NKT cells that were initially expanded under Th2 polarizing conditions could be reversed to a Th1 cytokine profile, indicating the plasticity of the cytokine profile of the human adult Valpha24(+) Vbeta11(+) NKT cell population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874013

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.

Authors:  Yoshinori Ikarashi; Akira Iizuka; Yumie Koshidaka; Yuji Heike; Yoichi Takaue; Mitsuzi Yoshida; Mitchell Kronenberg; Hiro Wakasugi
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

2.  Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.

Authors:  Kamiya Mehla; Jarrod Tremayne; James A Grunkemeyer; Kelly A O'Connell; Maria M Steele; Thomas C Caffrey; Xinyi Zhu; Fang Yu; Pankaj K Singh; Birgit C Schultes; Ragupathy Madiyalakan; Christopher F Nicodemus; Michael A Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2017-12-04       Impact factor: 6.968

Review 3.  Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors:  Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

4.  Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Authors:  Weihua Song; Hans J J van der Vliet; Yu-Tzu Tai; Rao Prabhala; Ruojie Wang; Klaus Podar; Laurence Catley; Masood A Shammas; Kenneth C Anderson; Steven P Balk; Mark A Exley; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 5.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

6.  Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.

Authors:  Michael Nowak; Mohammed S Arredouani; Adrian Tun-Kyi; Ingo Schmidt-Wolf; Martin G Sanda; Steven P Balk; Mark A Exley
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

7.  Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4.

Authors:  Akira Iizuka; Yoshinori Ikarashi; Mitsuzi Yoshida; Yuji Heike; Kazuyoshi Takeda; Gary Quinn; Hiro Wakasugi; Masanobu Kitagawa; Yoichi Takaue
Journal:  Immunology       Date:  2007-11-14       Impact factor: 7.397

8.  Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11.

Authors:  Carlos J Montoya; David Pollard; Jeffrey Martinson; Kumud Kumari; Clive Wasserfall; Candice B Mulder; Maria T Rugeles; Mark A Atkinson; Alan L Landay; S Brian Wilson
Journal:  Immunology       Date:  2007-07-28       Impact factor: 7.397

9.  Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.

Authors:  Hans J J van der Vliet; Ruojie Wang; Simon C Yue; Henry B Koon; Steven P Balk; Mark A Exley
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

10.  Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.

Authors:  Joanne E Croudace; Stuart M Curbishley; Manuela Mura; Carrie R Willcox; Petr A Illarionov; Gurdyal S Besra; David H Adams; David A Lammas
Journal:  BMC Immunol       Date:  2008-12-03       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.